OKLAHOMA CITY: Swiss drugmaker Roche has “renewed confidence” that drugs targeting potentially brain-destroying plaque can fight Alzheimer’s disease, following promising results with a product from a rival.
Pharmaceuticals head Daniel O’Day said on Wednesday Roche would look again at prospects for two of its experimental Alzheimer’s drugs, both of which suffered setbacks in 2014, in the wake of recent data on Biogen’s drug.
The U.S. biotech group made headlines last month with better-than-expected clinical trial results for its experimental Alzheimer’s medicine, aducanumab…